Senti Biosciences, Inc. (ticker: SNTI) is an NASDAQ-listed clinical research company. DredgeCap's structured extraction of SNTI's SEC filings surfaces 2 active risk signals, including 1 auditor-change signal, and 1 delisting/deregistration signal. SNTI reported $16K in revenue and -$4.22M for the period ending 2026-03-31, with operating cash flow of -$7.48M. Cash and equivalents stood at $8.94M (down 73.6% year-over-year). Total assets of $38.24M exceed total liabilities of $35.68M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
SNTI Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Senti Biosciences, Inc. (SNTI) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.